Afsaneh Barzi

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research communications

JCO oncology practice

Cost effectiveness and resource allocation : C/E

City of Hope

University of Texas School of Public Health (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

City of Hope Mar 23 2020

United States

Associate Professor of Medicine :: Medical Oncology

Education History

University of Texas School of Public Health Aug 01 2005 - Jun 05 2009

United States

PHD

Publications

Daniel H Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A Subramanian, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Daniel H Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A Subramanian, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Daneng Li, Christiana Joy Crook, Vincent Chung, Gagandeep Brar, Marwan G Fakih, Afsaneh Barzi, Laleh G Melstrom, Gagandeep Singh, Yuman Fong, Paul H Frankel, Mustafa Raoof
Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases. Future oncology (London, England) (2024)
Daniel H Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A Subramanian, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Daniel H Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A Subramanian, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Phase 1b Clinical Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Daniel H Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A Subramanian, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Aaron James Scott, Atrayee Basu Mallick, Efrat Dotan, Steven J Cohen, Philip J Gold, Howard S Hochster, Somasundaram Subramaniam, Afsaneh Barzi, George S Watts, Patrick J Blatchford, Wells A Messersmith
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). Cancer research communications 2 (10) (2022)
Aaron James Scott, Atrayee Basu Mallick, Efrat Dotan, Steven J Cohen, Philip J Gold, Howard S Hochster, Somasundaram Subramaniam, Afsaneh Barzi, George S Watts, Patrick J Blatchford, Wells A Messersmith
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). Cancer research communications 2 (10) (2022)
Afsaneh Barzi, Dongyun Yang, Anthony W Kim, Manish A Shah, Sarmad Sadeghi
Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ open gastroenterology 7 (1) (2021)
Howard Jack West, Yuan Angela Tan, Afsaneh Barzi, Debra Wong, Robert Parsley, Todd Sachs
Novel Program Offering Remote, Asynchronous Subspecialist Input in Thoracic Oncology: Early Experience and Insights Gained During the COVID-19 Pandemic. JCO oncology practice (2021)
Alberto Puccini, Kelsey Poorman, Mohamed E Salem, Davide Soldato, Andreas Seeber, Richard M Goldberg, Anthony Frank Shields, Joanne Xiu, Francesca Battaglin, Martin D Berger, Ryuma Tokunaga, Madiha Naseem, Afsaneh Barzi, Syma Iqbal, Wu Zhang, Shivani Soni, Jimmy J Hwang, Philip A Philip, Stefania Sciallero, Wolfgang Michael Korn, John L Marshall, Heinz-Josef Lenz
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clinical cancer research : an official journal of the American Association for Cancer Research 26 (22) (2020)
Afsaneh Barzi, Primo N Lara, Denice Tsao-Wei, Dongyun Yang, Inderbir S Gill, Siamak Daneshmand, Eric A Klein, Jacek K Pinski, David F Penson, David I Quinn, Sarmad Sadeghi
Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer 125 (21) (2019)
Yifan Xu, Joel W Hay, Afsaneh Barzi
Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost effectiveness and resource allocation : C/E 16 (2018)

Afsaneh Barzi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Afsaneh Barzi